Shanghai OPM Biosciences Past Earnings Performance
Past criteria checks 1/6
Shanghai OPM Biosciences has been growing earnings at an average annual rate of 14.4%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 16.7% per year. Shanghai OPM Biosciences's return on equity is 1.8%, and it has net margins of 13.3%.
Key information
14.4%
Earnings growth rate
-10.5%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 16.7% |
| Return on equity | 1.8% |
| Net Margin | 13.3% |
| Next Earnings Update | 26 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai OPM Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 287 | 38 | 116 | 33 |
| 30 Jun 24 | 265 | 40 | 108 | 37 |
| 31 Mar 24 | 255 | 49 | 94 | 40 |
| 31 Dec 23 | 243 | 54 | 81 | 42 |
| 30 Sep 23 | 243 | 65 | 71 | 41 |
| 30 Jun 23 | 269 | 90 | 71 | 39 |
| 31 Mar 23 | 290 | 104 | 68 | 37 |
| 31 Dec 22 | 294 | 105 | 65 | 32 |
| 30 Sep 22 | 285 | 97 | 57 | 29 |
| 30 Jun 22 | 277 | 95 | 55 | 23 |
| 31 Mar 22 | 244 | 76 | 52 | 20 |
| 31 Dec 21 | 213 | 60 | 51 | 19 |
| 31 Dec 20 | 125 | 12 | 30 | 21 |
| 31 Dec 19 | 59 | -12 | 18 | 21 |
| 31 Dec 18 | 34 | -42 | 57 | 7 |
Quality Earnings: 688293 has a large one-off gain of CN¥9.5M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 688293's current net profit margins (13.3%) are lower than last year (26.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688293 has become profitable over the past 5 years, growing earnings by 14.4% per year.
Accelerating Growth: 688293's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688293 had negative earnings growth (-41.8%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).
Return on Equity
High ROE: 688293's Return on Equity (1.8%) is considered low.